文献速递腹部技术与安全PETMR

[18F]FDG-PET/MRI对原发恶性肿瘤患者肝转移的诊断效能:系统评价与Meta分析

Diagnostic performance of [18F]FDG-PET/MRI for liver metastasis in patients with primary malignancy: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2019-02-04

该系统评价与Meta分析检索截至2017年12月31日的文献,纳入8篇原始研究,评估[18F]FDG-PET/MRI检测肝转移的诊断准确性并与PET/CT比较。基于患者的汇总敏感度99.2%、特异度98.6%,基于病灶的汇总敏感度95.4%、特异度99.3%;PET/MRI的敏感度(95.4% vs. 68.3%)和特异度(99.3% vs. 95.8%)高于PET/CT。总体诊断准确性高但存在显著异质性,需要进一步随机对照或前瞻性研究。

要点

  • 基于患者的汇总敏感度99.2%、特异度98.6%,基于病灶的汇总敏感度95.4%、特异度99.3%。
  • PET/MRI的敏感度(95.4% vs. 68.3%)和特异度(99.3% vs. 95.8%)高于PET/CT。
  • 使用DWI和肝细胞特异性对比剂注射后HBP图像的PET/MRI显著提高诊断准确性。

核心结论

  • [18F]FDG-PET/MRI对肝转移的诊断准确性总体较高,但研究间存在显著异质性;需要进一步随机对照研究或前瞻性研究探讨其与PET/CT比较的作用。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed和EMBASE数据库截至2017年12月31日,纳入8篇原始研究,其中7篇用于基于病灶分析、4篇用于基于患者分析;采用QUADAS-2评估研究质量,采用分层建模方法估计汇总敏感度和特异度,并与PET/CT比较。

诊断标准与关键数值

  • 基于患者的汇总敏感度99.2%(95% CI 31.4-100.0%,I²=89.4%)、特异度98.6%(95% CI 84.0-99.9%,I²=0.0%);基于病灶的汇总敏感度95.4%(95% CI 78.3-99.2%,I²=99.7%)、特异度99.3%(95% CI 93.8-99.9%,I²=96.5%)。PET/MRI与PET/CT比较:敏感度95.4% vs. 68.3%,特异度99.3% vs. 95.8%。Meta回归分析显示5个显著影响研究异质性的因素:研究对象特征、研究设计、MRI技术(DWI、注射肝特异性对比剂后HBP)、影像审阅方法和参考标准。

临床应用与阅片要点

  • 使用DWI和肝细胞特异性对比剂注射后HBP图像的PET/MRI可显著提高诊断准确性;PET/MRI的敏感度和特异度高于PET/CT。

局限性

  • 研究间存在显著异质性。
  • 需要进一步随机对照研究或前瞻性研究探讨PET/MRI与PET/CT比较在肝转移中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To systematically determine the diagnostic accuracy of 18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ([18F]FDG-PET/MRI) for the detection of liver metastases and evaluate the sources of heterogeneity in the reported results.

METHODS: PubMed and EMBASE databases were searched up until December 31, 2017, to identify original research studies reporting the diagnostic performance (Se and Sp) of PET/MRI for liver metastases, in comparison with PET/CT. Study quality was assessed using QUADAS-2. The summary Se and Sp of the studies were estimated using hierarchical modeling methods. To determine causes of study heterogeneity, the presence of a threshold effect was analyzed, and meta-regression analysis was performed.

RESULTS: Of 546 articles screened, eight suitable articles were identified, with seven for per-lesion analysis, and four for per-patient analysis. The meta-analytic summary Se and Sp for per-patient-based analysis were 99.2% (95% CI, 31.4-100.0%, I2 = 89.4%) and 98.6% (95% CI, 84.0-99.9%, I2 = 0.0%), respectively, while for per-lesion-based analysis they were 95.4% (95% CI, 78.3-99.2%, I2 = 99.7%) and 99.3% (95% CI, 93.8-99.9%, I2 = 96.5%). PET/MRI showed higher Se (95.4% vs. 68.3%) and Sp (99.3% vs. 95.8%) than PET/CT. Meta-regression analysis showed five significant factors affecting study heterogeneity: study subject characteristics, study design, MRI technique (DWI, HBP after injection of liver-specific contrast media), imaging review method, and reference standard.

CONCLUSION: The diagnostic accuracy of [18F]FDG-PET/MRI for liver metastasis was high overall, but substantial heterogeneity was found. Further randomized controlled studies or prospective studies are needed to investigate the role of PET/MRI in liver metastasis in comparison with PET/CT.

KEY POINTS: • [ 18 F]FDG-PET/MRI has high meta-analytic Se and Sp for the diagnosis of liver metastasis. • PET/MRI using DWI and HBP images significantly increased diagnostic accuracy. • Study heterogeneity was associated with subject characteristics, study design, MRI technique, image review method, and reference standard.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Hong SB, Choi SH, Kim KW, et al. Diagnostic performance of [18F]FDG-PET/MRI for liver metastasis in patients with primary malignancy: a systematic review and meta-analysis. Eur Radiol. 2019. PMID: 30715585. doi:10.1007/s00330-018-5909-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。